Literature DB >> 9690673

Cyclin-dependent kinase 5 and mitogen-activated protein kinase in glial cytoplasmic inclusions in multiple system atrophy.

S Nakamura1, Y Kawamoto, S Nakano, I Akiguchi, J Kimura.   

Abstract

Glial cytoplasmic inclusions (GCI) characteristically occur in the oligodendrocytes of patients with multiple system atrophy (MSA). However, the molecular mechanisms underlying GCI formation are unknown. To investigate whether these inclusions are related to proline-directed protein kinases that have been associated with neuronal inclusion bodies in some other neurodegenerative diseases, we immunohistochemically probed tissue samples from MSA brains with a panel of antibodies against cyclin-dependent kinases and mitogen-activated protein kinase. We unexpectedly detected cyclin-dependent kinase 5- (cdk5) and mitogen-activated protein kinase- (MAPK) immunoreactivities in GCI. We also found TAU1 immunoreactivity in GCI, and a strong expression of microtubule-associated protein (MAP) 2 immunoreactivity in oligodendrocytes of MSA brains. This immunoreactivity was not observed in the normal or neurological controls. The accumulated evidence suggest a close association between GCI and the microtubular cytoskeleton. Cdk5 phosphorylates tau and MAP2, and MAPK is capable of phosphorylating MAP2. The present results suggest that the aberrant or ectopic expression of cdk5 and MAPK causes abnormal phosphorylation of microtubular cytoskeletal proteins, thus leading to GCI formation in affected oligodendrocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690673     DOI: 10.1097/00005072-199807000-00006

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  12 in total

1.  Hippocampal glycogen synthase kinase 3β is critical for the antidepressant effect of cyclin-dependent kinase 5 inhibitor in rats.

Authors:  Gang Li; Ting Liu; Xiangqian Kong; Lei Wang; Xing Jin
Journal:  J Mol Neurosci       Date:  2014-02-22       Impact factor: 3.444

2.  Insulin resistance and exendin-4 treatment for multiple system atrophy.

Authors:  Fares Bassil; Marie-Hélène Canron; Anne Vital; Erwan Bezard; Yazhou Li; Nigel H Greig; Seema Gulyani; Dimitrios Kapogiannis; Pierre-Olivier Fernagut; Wassilios G Meissner
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

Review 3.  The neuropathology of multiple system atrophy and its therapeutic implications.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Auton Neurosci       Date:  2017-11-10       Impact factor: 3.145

Review 4.  Multiple system atrophy: cellular and molecular pathology.

Authors:  D J Burn; E Jaros
Journal:  Mol Pathol       Date:  2001-12

5.  Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia.

Authors:  D W Miller; J M Johnson; S M Solano; Z R Hollingsworth; D G Standaert; A B Young
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

6.  Glial cell inclusions and the pathogenesis of neurodegenerative diseases.

Authors:  David W Miller; Mark R Cookson; Dennis W Dickson
Journal:  Neuron Glia Biol       Date:  2004-02

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 8.  Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders?

Authors:  Benjamin Ettle; Johannes C M Schlachetzki; Jürgen Winkler
Journal:  Mol Neurobiol       Date:  2015-05-13       Impact factor: 5.590

Review 9.  Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1.

Authors:  Kurt A Jellinger
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 10.  Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions.

Authors:  Seiji Kaji; Takakuni Maki; Tomoyuki Ishimoto; Hodaka Yamakado; Ryosuke Takahashi
Journal:  Transl Neurodegener       Date:  2020-02-17       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.